Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

BACKGROUND: There is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize neoantigens derived from tumor somatic mutations. Thus, the frequencies or characteristics of tumor-reactive, mutation-specific CD8+ T cells could...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Fehlings, Michael, Jhunjhunwala, Suchit, Kowanetz, Marcin, O’Gorman, William E., Hegde, Priti S., Sumatoh, Hermi, Lee, Boon Heng, Nardin, Alessandra, Becht, Etienne, Flynn, Susan, Ballinger, Marcus, Newell, Evan W., Yadav, Mahesh
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6740011/
https://ncbi.nlm.nih.gov/pubmed/31511069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0695-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados